Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...

Radionuclide drug conjugates (RDCs) have emerged as transformative agents that integrate diagnosis and therapy into a single ...

Next-generation biologics, such as bispecifics, fusion proteins, and multi-specifics, have multiple functionalities that ...

You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...

Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

Organic–inorganic-hybridized nanocrystals are a valuable class of new materials that are suitable for addressing many emerging challenges in biological and material sciences 1,2. Nanogold and quantum ...

NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate (PDC) ...

Antibody-drug conjugates are a new kind of targeted treatment for multiple myeloma. They deliver powerful cancer-killing drugs straight to myeloma cells, and they help your own immune system attack ...

The global antibody drug conjugates market size was US$ 4,990.8 million in 2021. The global antibody drug conjugates s market size is forecast to reach US$ 33,150.3 million by 2030, growing at a CAGR ...

Please provide your email address to receive an email when new articles are posted on . The most common ocular adverse events with antibody-drug conjugates involve the ocular surface. The mainstay of ...